In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

A special edition of the journal Science focuses on women's health, including links between estrogen and dementia, at a time ...

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

Diagnosing Alzheimer's disease before people have any symptoms is possible, but brings up concerns when so few treatments are ...

After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...

The U.K has released a huge repository of children’s genomic data after sequencing blood samples from three large cohorts recruited at birth and followed across three decades. The power of the data is ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...

Among the stocks on Morningstar’s list, the average change in fair value estimate was a 1.99% increase, above the 10-year ...

Australia’s Therapeutic Goods Administration (TGA) has once again decided against approving Eisai Australia Pty Ltd.’s amyloid beta binder, Leqembi (lecanemab), for treating patients with mild ...

Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records show, as the pharmaceutical company shaves off 7% of its U.S workforce.

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...